Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Trial Profile

Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Hydrocortisone (Primary)
  • Indications Adrenal insufficiency; Congenital adrenal hyperplasia
  • Focus Adverse reactions; Registrational
  • Acronyms Infacort004
  • Sponsors Diurnal
  • Most Recent Events

    • 13 Feb 2018 According to a Diurnal media release, received marketing authorisation (PUMA) for Alkindi from the European Commission (EC).
    • 15 Dec 2017 According to a Diurnal media release, the CHMP of the EMA, has issued a positive opinion to the European Commission recommending Alkindi (Infacort hydrocortisone granules in capsules for opening) as replacement therapy for paediatric adrenal insufficiency. The positive opinion from the CHMP is based on review of data from this trial. The final decision on the paediatric use marketing authorisation (PUMA) from the European Commission is anticipated in February 2018.
    • 07 Nov 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top